Growth hormone therapy monitoring may need recalibration as new measurement techniques reveal that bioactive IGF-I levels don't always mirror the total IGF-I concentrations currently used to assess treatment safety. This finding could reshape how clinicians balance therapeutic benefits against potential long-term risks in children receiving growth hormone treatment.
Researchers analyzed 570 healthy children and 126 growth hormone-deficient patients, establishing the first pediatric reference ranges for bioactive IGF-I using kinase receptor activation assays. While bioactive IGF-I correlated moderately with total IGF-I measurements (correlation coefficients 0.56-0.61), the relationship wasn't perfectly aligned. Notably, only 13% of treated patients showed elevated bioactive IGF-I levels above normal ranges, compared to 25% showing elevated total IGF-I. Just nine patients had both measures elevated simultaneously.
This divergence challenges current monitoring protocols that rely exclusively on total IGF-I measurements to guide dosing decisions. Bioactive IGF-I represents the fraction actually capable of cellular signaling, potentially offering more precise risk assessment than measuring the total circulating pool. The Copenhagen study also revealed that bioactive IGF-I correlated negatively with IGF-II, suggesting complex regulatory interactions that total measurements miss.
For pediatric endocrinologists, these findings suggest current safety thresholds may be overly conservative, potentially limiting therapeutic benefits for some children. However, the clinical implications remain unclear since long-term outcome data using bioactive measurements don't exist. This represents incremental but potentially important progress toward more sophisticated growth hormone monitoring, though widespread clinical adoption would require extensive validation studies and new reference standards.